For years, the interventional cardiology community has wrestled with a complex clinical puzzle: what is the optimal timing for treating secondary blockages in patients suffering from an ST-elevation myocardial infarction (STEMI)? While clinical guidelines from major international bodies have increasingly leaned toward immediate complete revascularization, a provocative new meta-analysis suggests that this "all-in-one" approach may come at a significant, and potentially lethal, cost.
According to research recently published in Circulation: Cardiovascular Interventions, patients who receive immediate complete revascularization for multivessel disease during a STEMI may face a higher short-term risk of cardiac mortality compared to those treated with a staged strategy. As the evidence base grows, prominent experts are calling for a reassessment of current standard practices, urging clinicians to view the staged procedure as the default "gold standard" rather than the exception.
The Core Findings: A Shift in the Evidence Landscape
The meta-analysis, led by Dr. Mohammed Elbahloul of Kafr El-Shaikh University, Egypt, synthesized data from nine randomized controlled trials involving 4,213 patients. The study sought to resolve the conflicting signals emerging from recent major trials.
The results paint a concerning picture for proponents of "one-and-done" intervention. While there were no statistically significant differences in major adverse cardiovascular and cerebrovascular events (MACCE), recurrent myocardial infarction (MI), or repeat revascularization, the data on mortality were stark. At 30 days, patients undergoing immediate complete revascularization faced a more than twofold increase in the risk of cardiac mortality compared to those whose secondary lesions were addressed in a later, staged procedure.
Specifically, in the cohort of 1,811 patients where cardiac mortality was tracked, 2.6% of those in the immediate revascularization group died of cardiac causes within 30 days, compared to just 1.2% in the staged group. This creates a risk ratio of 2.19, a figure that is difficult for clinicians to ignore.
A Historical Chronology of the Debate
The tension between immediate and staged revascularization has been building for nearly a decade, fueled by a series of high-profile, and sometimes contradictory, clinical trials.
The Shadow of CULPRIT-SHOCK
The foundation for current skepticism regarding immediate multivessel intervention was arguably laid by the landmark CULPRIT-SHOCK trial. That study investigated patients with acute MI complicated by cardiogenic shock—a high-acuity, high-mortality population. The findings were decisive: immediate, extensive revascularization of all significant nonculprit lesions was associated with worse outcomes, including higher rates of death and severe renal failure.
The Proliferation of "Non-Inferiority" Trials
In the years following, researchers turned their attention to stable STEMI patients—those not in cardiogenic shock. Trials like MULTISTARS AMI and BIOVASC suggested that immediate multivessel PCI was "non-inferior" to staged procedures. These findings were eagerly adopted into clinical guidelines, leading the American College of Cardiology (ACC) and the American Heart Association (AHA) to issue a class 1 recommendation for complete revascularization, with a preference for immediate intervention in some scenarios.
However, the consensus began to fracture as more data emerged. The OPTION-STEMI trial found that immediate revascularization failed to meet the bar for non-inferiority, and the iMODERN trial, which utilized physiological guidance (iFR), showed no benefit over deferred imaging-guided strategies.
Deconstructing the Data: The "Procedural MI" Problem
One of the most compelling arguments raised by senior investigator Dr. Gregg Stone (Icahn School of Medicine at Mount Sinai) is that the existing clinical trials may be fundamentally flawed in their interpretation.
Dr. Stone argues that the inclusion of "myocardial infarction" as a primary endpoint in many of these trials has "obfuscated" the true clinical picture. In the acute setting of a STEMI, biomarkers like troponin are already elevated and rapidly rising. Furthermore, ST-segments remain altered due to the index event. Under these conditions, it is virtually impossible to detect a secondary, procedure-related myocardial infarction caused by the intervention on a non-culprit artery.
"You could do harm in the immediate procedure by doing another intervention in a non-infarct-related artery," Dr. Stone explains, "but it would be very hard to pick that up with any objective test." Consequently, he suggests that many of the trials that appeared to support immediate revascularization may have been biased by an inability to accurately count procedural MI events, thereby masking the harm being done to the patient.
Official Responses and Clinical Guidelines
The current guidelines reflect the uncertainty that has plagued this field. The ACC/AHA guidelines currently give complete revascularization a class 1 (level A) recommendation. However, the specific timing—whether to perform it immediately or during a later stage—carries a class 2b recommendation, indicating that while the strategy is suggested, the evidence base is relatively weak.
Dr. Sunil Rao, of the NYU Langone Health System, who chaired the ACC/AHA writing committee, acknowledged the conflict. "The current meta-analysis goes against MULTISTARS to some degree," Dr. Rao noted. He points out that the MULTISTARS trial showed a significant benefit in terms of reducing unplanned revascularizations, which drove its positive outcome. However, he admits that recurrent MI is notoriously difficult to adjudicate in the setting of a STEMI, which aligns with Dr. Stone’s critique.
Current Institutional Practices
Despite the high-level recommendations, many leading centers have not adopted a "routine immediate" approach. At Dr. Stone’s institution, the default remains a staged approach. Immediate revascularization is reserved for "very selected circumstances," such as when a patient presents with multiple plaque ruptures or when a non-culprit artery is so severely stenosed (e.g., 99%) that it is actively compromising blood flow.
Similarly, Dr. Rao notes that his center tailors the decision to the specific anatomy of the patient. "If the non-culprit disease is high risk, we tend to stage during the same hospitalization," he says. "If it is lower risk, we stage as an outpatient. We rarely perform non-culprit PCI during the same setting as the index culprit PCI."
Clinical Implications: Why Timing Matters
The implications of this meta-analysis are profound for the field of interventional cardiology. If the signal of increased early mortality is validated in future research, the current "one-and-done" approach may need to be dismantled.
- Patient Safety First: The primary lesson is that in the absence of hemodynamic instability, there is no urgent need to revascularize non-culprit lesions. By separating the procedures, clinicians may reduce the physiological stress on the patient, limit contrast exposure, and minimize the risk of procedural complications.
- Rethinking Endpoints: The scientific community must reconsider how it defines and measures "success" in future trials. If procedural MI cannot be reliably measured in the acute phase, trials should prioritize hard endpoints like all-cause mortality and cardiac death over 30 days and 1 year.
- Refining Guidelines: As Dr. Stone suggests, the current guidelines are based on an "insufficient evidence base." With only about 4,200 patients analyzed across nine trials, the medical community lacks the robust, large-scale randomized data required to justify a class 1, level A recommendation for immediate intervention.
- A Shift in Strategy: The consensus is moving toward the view that "complete revascularization" is a goal, but "immediate" is a tactic that should be used sparingly.
Conclusion: A Call for Caution
The meta-analysis by Dr. Elbahloul and his colleagues serves as a vital reminder that in the high-stakes environment of the cardiac catheterization lab, speed is not always synonymous with safety. While the allure of finishing the job during a single procedure is understandable from both a logistical and patient-convenience perspective, the potential for increased mortality cannot be dismissed.
For now, the message to interventionalists is clear: take a breath. In the majority of STEMI cases with multivessel disease, the staged approach offers a safer, more controlled pathway to patient recovery. As the field moves forward, the focus must remain on generating high-quality, long-term data that prioritizes patient survival over procedural efficiency. The era of reflexively performing multivessel PCI during the index STEMI may be coming to an end, replaced by a more nuanced, anatomy-driven strategy that treats the patient, not just the angiogram.
